Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review.
Naoto Minematsu, Yoko Imai, Toshiyuki Hirano et al.
✦ AI-curated · Sources linked
Case in brief
The abstract describes a case of lung squamous cell carcinoma (SQC) with an EGFR mutation, alongside a systematic review of 34 eligible cases. It does not provide the individual patient’s presentation, diagnostic findings, treatment course, or outcome. Across the reviewed cases, third-generation EGFR tyrosine kinase inhibitors (TKIs) showed greater initial responsiveness than earlier-generation TKIs, with efficacy reported across de novo and adenocarcinoma-transformed SQC and across EGFR mutation types.
What made this case unusual
EGFR mutations are uncommon in lung SQC, and the review addresses the uncertain role of third-generation EGFR-TKIs in this setting.
Diagnostic / clinical pearl
In EGFR-mutated lung SQC, distinguish de novo SQC from adenocarcinoma-transformed SQC; the review reports TKI efficacy across both forms and mutation types.
Why it matters
The authors conclude that third-generation EGFR-TKIs are effective against de novo SQC and are a plausible treatment option for transformed SQC.